Association between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing

Sharad Khurana; Jason C. Sluzevich; Rong He; Danielle K. Reimer; Mohamed A. Kharfan-Dabaja; James M. Foran; Liuyan Jiang

doi:10.1001/jamadermatol.2020.0544

Association between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing

Sharad Khurana, Jason C. Sluzevich, Rong He, Danielle K. Reimer, Mohamed A. Kharfan-Dabaja, James M. Foran, Liuyan Jiang

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	817-819
Number of pages	3
Journal	JAMA Dermatology
Volume	156
Issue number	7
DOIs	https://doi.org/10.1001/jamadermatol.2020.0544
State	Published - Jul 2020

ASJC Scopus subject areas

Dermatology

Access to Document

10.1001/jamadermatol.2020.0544

Cite this

@article{d7654613dd7345049417541f4e578d28,

title = "Association between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing",

author = "Sharad Khurana and Sluzevich, {Jason C.} and Rong He and Reimer, {Danielle K.} and Kharfan-Dabaja, {Mohamed A.} and Foran, {James M.} and Liuyan Jiang",

note = "Funding Information: Funding/Support: This research was supported in part by the Intramural Research Program of the National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Environmental Health Sciences. Role of the Funder/Sponsor: The Intramural Research Program of the National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Environmental Health Sciences played no part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank the patients for granting permission to publish this information. We also thank Marcus Chen, MD, National Heart, Lung, and Blood Institute, National Institutes for Health, for assistance with computed tomographic imaging and Dominique C. Pichard, MD, Dermatology Branch, National Institutes for Health, for her help in reviewing the final manuscript. Funding Information: Conflict of Interest Disclosures: Dr Kharfan-Dabaja has served as a consultant for Daiichi Sankyo and Pharmacyclics. Dr Foran has received personal fees from Agios, Pfizer, Stemline, Novartis, and AbbVie and grants from Boehringer Ingelheim, Xencor, Kura, Takeda Millennium, and Actinium. No other conflict of interest disclosures were reported.",

year = "2020",

month = jul,

doi = "10.1001/jamadermatol.2020.0544",

language = "English (US)",

volume = "156",

pages = "817--819",

journal = "JAMA Dermatology",

issn = "2168-6068",

publisher = "American Medical Association",

number = "7",

}

TY - JOUR

T1 - Association between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing

AU - Khurana, Sharad

AU - Sluzevich, Jason C.

AU - He, Rong

AU - Reimer, Danielle K.

AU - Kharfan-Dabaja, Mohamed A.

AU - Foran, James M.

AU - Jiang, Liuyan

N1 - Funding Information: Funding/Support: This research was supported in part by the Intramural Research Program of the National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Environmental Health Sciences. Role of the Funder/Sponsor: The Intramural Research Program of the National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Environmental Health Sciences played no part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank the patients for granting permission to publish this information. We also thank Marcus Chen, MD, National Heart, Lung, and Blood Institute, National Institutes for Health, for assistance with computed tomographic imaging and Dominique C. Pichard, MD, Dermatology Branch, National Institutes for Health, for her help in reviewing the final manuscript. Funding Information: Conflict of Interest Disclosures: Dr Kharfan-Dabaja has served as a consultant for Daiichi Sankyo and Pharmacyclics. Dr Foran has received personal fees from Agios, Pfizer, Stemline, Novartis, and AbbVie and grants from Boehringer Ingelheim, Xencor, Kura, Takeda Millennium, and Actinium. No other conflict of interest disclosures were reported.

PY - 2020/7

Y1 - 2020/7

UR - http://www.scopus.com/inward/record.url?scp=85084795650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084795650&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2020.0544

DO - 10.1001/jamadermatol.2020.0544

M3 - Letter

C2 - 32374348

AN - SCOPUS:85084795650

SN - 2168-6068

VL - 156

SP - 817

EP - 819

JO - JAMA Dermatology

JF - JAMA Dermatology

IS - 7

ER -

Association between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this